Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
Massimo VolpeKostantinos Tsioufis

Abstract

Despite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (< 140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbidities contribute to the disparity between the potential and actual BP control rate. Previously we published a practical therapeutic platform for the treatment of hypertension based on clinical evidence, guidelines, best practice and clinical experience. This platform provides a personalised treatment approach and can be used to improve BP control and simplify treatment. It uses long-acting, effective and well-tolerated angiotensin receptor blocker (ARB) olmesartan, in combination with a calcium channel blocker amlodipine, and/or a thiazide diuretic hydrochlorothiazide. These drugs were selected based on the availability in most...Continue Reading

References

Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jun 29, 2004·The American Journal of Cardiology·Donald M Lloyd-JonesDaniel Levy
May 26, 2005·Current Hypertension Reports·Paolo VerdecchiaRoberto Gattobigio
Jun 11, 2005·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Stella StabouliNikos Zakopoulos
Dec 7, 2005·Journal of Hypertension·Giuseppe ManciaAlberto Zanchetti
Sep 1, 2006·American Journal of Hypertension·Mari TomiyamaYuhei Kawano
Feb 21, 2007·Hypertension·Neil ChapmanUNKNOWN Anglo-Scandinavian Cardiac Outcomes Trial Investigators
Sep 22, 2007·Journal of Hypertension·Alberto ZanchettiGiuseppe Vargiu
Feb 23, 2008·American Journal of Hypertension·Vasilios KotsisNikos Zakopoulos
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Nov 13, 2008·The New England Journal of Medicine·Barry M MassieUNKNOWN I-PRESERVE Investigators
Dec 31, 2008·Hypertension·Norm R C CampbellUNKNOWN Canadian Hypertension Education Program Outcomes Research Task Force
Apr 14, 2010·Hypertension·Lydie HazanUNKNOWN Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension Study Group
Jan 25, 2011·Expert Opinion on Drug Safety·Jürgen ScholzeReinhold Kreutz
Feb 8, 2011·Lancet·Goodarz DanaeiUNKNOWN Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure)
Feb 23, 2013·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeUNKNOWN Italian Society of Hypertension
Mar 29, 2013·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeUNKNOWN Italian Society of Hypertension
Apr 5, 2013·Multidisciplinary Respiratory Medicine·Giorgio FumagalliClaudio Maria Sanguinetti
Feb 18, 2014·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeAthanasios J Manolis
Mar 20, 2014·The Journal of Clinical Hypertension·Martin G Myers, Sheldon W Tobe
Mar 26, 2014·Hypertension·Alexandre PersuUNKNOWN European Network Coordinating research on REnal Denervation Consortium

❮ Previous
Next ❯

Citations

Aug 30, 2019·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Valentina PerroneMassimo Volpe
May 4, 2020·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Vincenzo CesarioGiuliano Tocci
Nov 10, 2020·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Giuliano TocciMassimo Volpe
Nov 22, 2020·The Journal of Clinical Hypertension·Ann Z BauerDavid Kriebel
Mar 13, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Vivianne PrestaMassimo Volpe

❮ Previous
Next ❯

Software Mentioned

SPRINT

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
Massimo VolpeAthanasios J Manolis
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
Massimo VolpeGiuliano Tocci
Therapeutic Advances in Cardiovascular Disease
Benjamin J EpsteinNancy L Borja-Hart
© 2022 Meta ULC. All rights reserved